We assign a fundamental rating of 2 out of 10 to ALLK. ALLK was compared to 525 industry peers in the Biotechnology industry. While ALLK seems to be doing ok healthwise, there are quite some concerns on its profitability. ALLK does not seem to be growing, but still is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -119.89% | ||
| ROE | -146.95% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -20.1 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.81 | ||
| Quick Ratio | 4.81 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ChartMill assigns a fundamental rating of 2 / 10 to ALLK.
ChartMill assigns a valuation rating of 1 / 10 to ALLAKOS INC (ALLK). This can be considered as Overvalued.
ALLAKOS INC (ALLK) has a profitability rating of 0 / 10.